|
| Clinical Trials: Open Enrollment |
| The following is a listing of all trials currently enrolling brain tumor patients at UCLA. |
|
|
|
|
| What clinical trials are available at UCLA Neuro-Oncology? |
Choosing to participate in a clinical trial is an important, personal decision. It is often helpful to talk to a physician, family members, or friends about deciding to join a trial. After identifying some trial options, the next step is to contact the study research staff and ask questions about specific trials.
For more information about any of the UCLA Neuro-Oncology Program’s clinical trials listed, please contact Emese Filka, Clinical Trials Coordinator, at (310) 794-3521
|
| Study Agent | IRB ID | Trial:Details | | NONE | 03-04-057 | (NABTC 01-07) A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas. [R6 dated 8May07] : | | OSI-774 | 05-01-095 | (NABTC 04-02) Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients with Recurrent Malignant Glioma. (R4 dated 7May07) : | | RAD001 Novartis | 07-04-070 | (CRAD001C2410) A Pilot Multicenter Phase I/II Trial of RAD001 in Patients with Recurrent Glioblastoma Multiforme [R1 versio 18Oct06]: | | Sorafenib in combination w/OSI-774 or R115777 or CCI-779 | 06-04-030 | [NABTC 05-02] Ph I/II Studies of BAY 43-9006 (Sorafenib) in Combination with OSI-774, R115777 or CCI-779 in Patients with Recurrent Glioblastoma Multiforme or Gliosarcoma. [R1 dated 23Aug06; R2 dated 2Nov06]: | | Sorafenib in combination with OSI-774, R115777 or CCI-779 | 06-04-030 | (NABTC 05-02) Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination with OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients with Recurrent Glioblastoma Multiforme or Gliosardcoma [R3 dated 17Apr07]: | | TARCEVA (erlotinib HCl) | 06-04-104 | (OSI3781s) Ph I/II, Dual-Center, Open-Label Trial of the Safet and Efficacy of Tarceva TM Plus Sirolimus in Patients with Recurrent Malignant Glioma Not on P450-Inducing Anti-Epileptics. [version24Mar06] : | | Vorinostat | 05-12-061 | (NABTC 04-03) A Phase I Study of Vorinostat (SAHA) in Combination with Temozolomide in Patients with Malignant Gliomas. [R6 dated 15Feb07] : | | Vorinostat in combination with Temozolomide | 05-12-061 | (NABTC 04-03) Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in Combination with Temozolomide in Patients with Malignant Gliomas. [R3 dated 12Jun06] : | | XL765 and Temozolomide | 08-01-061 | [XL765-002] Ph I Dose-Escalation Study of XL765 in Combination with Temozolomide in Subjects with Malignant Glioma. [R1 version 15Apr08]: | | XL765 and Temozolomide | 08-01-061 | [XL765-002] Ph I Dose-Escalation Study of XL765 in Combination with Temozolomide in Subjects with Malignant Gliomas. (R1 dated 15Apr08): |
|
|
|
|
